financetom
Business
financetom
/
Business
/
Tata Power completes sale of its defence biz to Tata Advanced Systems
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tata Power completes sale of its defence biz to Tata Advanced Systems
Nov 2, 2020 4:39 AM

Tata Power on Monday said it has completed the sale of its defence business to Tata Advanced Systems. Tata Advanced Systems is a wholly-owned subsidiary of Tata Sons. ”The sale was completed as per a Scheme of Arrangement, which was approved by the National Company Law Tribunal at Mumbai and Hyderabad in December 2019 and March 2020, respectively,” Tata Power said in a regulatory filing. The company said it is expected to receive an enterprise value of Rs 1,076 crore as an upfront payment.

Balance consideration is subject to completion of achieving certain milestones specified in the agreements, the company added. Tata Power said the sale of defence business is part of the company’s ongoing strategic plan to monetise its non-core assets and reduce overall leverage.

”The sale proceeds will help the company to reduce leverage and increase focus in the core business areas like renewable generation, distribution and new service-led businesses which will bring greater value for our shareholders,” Praveer Sinha, CEO and Managing Director, Tata Power said. Strategic Engineering Division (SED) is a non-core defence electronics division of the company, engaged in business of indigenous design, development, production, integration, supply and life cycle support of mission-critical defence systems.

The key products include manufacturing and assembling missile launchers, electronic warfare, night vision systems and gun systems. SED has three dedicated manufacturing units — Bangalore Electronic City, Vemagal in Karnataka (under construction) and an SEZ near Bengaluru (under construction).

First Published:Nov 2, 2020 1:39 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mattr Prices $129.3 Million Offering of Debt Subscription Receipts
Mattr Prices $129.3 Million Offering of Debt Subscription Receipts
Dec 6, 2024
09:05 AM EST, 12/06/2024 (MT Newswires) -- Mattr ( MTTRF ) on Friday priced an offering of 125,000 debt subscription receipts at $1,034 each, including accrued but unpaid interest, for $129.3 million in proceeds. The company plans to use the proceeds to pay a portion of the purchase price for its previously announced indirect acquisition of AmerCable, which is expected...
Ubisoft shareholders in talks over possible buyout terms, sources say
Ubisoft shareholders in talks over possible buyout terms, sources say
Dec 6, 2024
* Guillemot family seen wanting to retain control in buyout * Tencent ( TCTZF ) undecided on increasing stake * Minority shareholders push for sale amid stock decline By Amy-Jo Crowley and Julie Zhu LONDON/HONG KONG, Dec 6 (Reuters) - Shareholders of Ubisoft Entertainment SA are considering how to structure a possible buyout of the Assassin's Creed video game maker...
Sector Update: Consumer Stocks Advance Pre-Bell Friday
Sector Update: Consumer Stocks Advance Pre-Bell Friday
Dec 6, 2024
09:05 AM EST, 12/06/2024 (MT Newswires) -- Consumer stocks were advancing pre-bell Friday as the Consumer Staples Select Sector SPDR Fund ( XLP ) was up 0.1% and the Consumer Discretionary Select Sector SPDR Fund ( XLY ) was 0.8% higher recently. Lululemon athletica (LULU) shares were over 8% higher after the company reported a surge in fiscal Q3 earnings...
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
Dec 6, 2024
On Friday, the FDA accepted and granted Priority Review AstraZeneca Plc's ( AZN ) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) for patients with muscle-invasive bladder cancer (MIBC). The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the second quarter of 2025. The supplement application is based on data from the NIAGARA...
Copyright 2023-2025 - www.financetom.com All Rights Reserved